Elan sues Biogen Idec over alleged breach of Tysabri partnership
This article was originally published in Scrip
Elan has filed a suit against Biogen Idec in federal court in New York, seeking to protect its interests in the multiple sclerosis drug Tysabri (natalizumab). It is seeking to prevent a possible termination of its partnership with Biogen Idec for the drug following Johnson & Johnson's proposed $1.5 billion investment in Elan.
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.